Search Results

You are looking at 41 - 50 of 199 items for :

  • "Metastatic breast cancer" x
Clear All
Full access

Julie R. Gralow, J. Sybil Biermann, Azeez Farooki, Monica N. Fornier, Robert F. Gagel, Rashmi Kumar, Georgia Litsas, Rana McKay, Donald A. Podoloff, Sandy Srinivas and Catherine H. Van Poznak

Tc has emerged Figure 3 Algorithm for imaging for cancer patients in the United States. Modified from Hamaoka T, Madewell JE, Podoloff DA, et al. Bone imaging in metastatic breast cancer. J Clin Oncol 2004;22:2942. because of the

Full access

Guidelines in Oncology: Hodgkin Lymphoma. Version 2.2015 . Available at: NCCN.org . Accessed December 8, 2015 . NCCN, in Collaboration with Pfizer, Awards 10 Grants for Provider Performance and Quality in Treatment of Metastatic Breast Cancer

Full access

Robert W. Carlson and on behalf of the NCCN Breast Cancer Panel

targeting the HER2 receptor with trastuzumab resulted in improved antitumor efficacy compared with chemotherapy alone in metastatic breast cancer overexpressing HER2. 1 This was rapidly followed by the initial reports of multigene array testing that showed

Full access

Harold J. Burstein

health care. Some have argued that the true costs of oncology treatment are difficult to assess. Consider, for instance, administration of chemotherapy for metastatic breast cancer. One would have to know the price of the chemotherapeutic agent; cost of

Full access

Jilma Patrick and Seema Ahsan Khan

radiotherapy) may improve survival when used in conjunction with effective systemic therapy. These data, along with the relative lack of morbidity of breast surgical procedures and the fact that patients with metastatic breast cancer are living longer with

Full access

Robert W. Carlson, D. Craig Allred, Benjamin O. Anderson, Harold J. Burstein, W. Bradford Carter, Stephen B. Edge, John K. Erban, William B. Farrar, Lori J. Goldstein, William J. Gradishar, Daniel F. Hayes, Clifford A. Hudis, Mohammad Jahanzeb, Krystyna Kiel, Britt-Marie Ljung, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Lisle M. Nabell, Lori J. Pierce, Elizabeth C. Reed, Mary Lou Smith, George Somlo, Richard L. Theriault, Neal S. Topham, John H. Ward, Eric P. Winer and Antonio C. Wolff

-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease . J Clin Oncol 1999 ; 17 : 2639 – 2648 . 48 Slamon DJ Leyland-Jones B Shak S . Use of chemotherapy plus a monoclonal antibody against HER2 for

Full access

Christopher E. Desch

– 506 . 9. Norum J Risberg T Olsen JA . A monoclonal antibody against HER-2 (traztuzumab) for metastatic breast cancer: a model-based cost-effectiveness analysis . Ann Oncol 2005 ; 16 : 909 – 914 . 10. Mayor S . NICE approves

Full access

NCCN Breast Cancer Panel Reaffirms Current Position and Recommendation Regarding the Use of Bevacizumab in Metastatic Breast Cancer The Expert Breast Cancer Panel of the NCCN met July 10–12, 2011, in Philadelphia, Pennsylvania. The

Full access

Aki Morikawa and Andrew D. Seidman

for patients with TNBC (hazard ratio [HR], 0.83; P <.05). 29 Eribulin is a halichondrin B analogue that perturbs microtubule dynamics. It demonstrated a survival benefit in heavily pretreated metastatic breast cancer (MBC) compared with the

Full access

#NCCNPolicy. NCCN Announces Projects Funded for Metastatic Breast Cancer Grant Program, in Collaboration With Pfizer The NCCN Oncology Research Program (ORP) recently announced the proposals that were selected to receive funding, in collaboration with Pfizer